TY - JOUR
T1 - Neurodevelopmental and growth outcomes after invasive Group B Streptococcus in early infancy
T2 - A multi-country matched cohort study in South Africa, Mozambique, India, Kenya, and Argentina
AU - GBS long term outcomes LMIC collaborative group
AU - Paul, Proma
AU - Chandna, Jaya
AU - Procter, Simon R.
AU - Dangor, Ziyaad
AU - Leahy, Shannon
AU - Santhanam, Sridhar
AU - John, Hima B.
AU - Bassat, Quique
AU - Bramugy, Justina
AU - Bardají, Azucena
AU - Abubakar, Amina
AU - Nasambu, Carophine
AU - Libster, Romina
AU - Yanotti, Clara Sánchez
AU - Seedat, Farah
AU - Horváth-Puhó, Erzsébet
AU - Hossain, A. K.M.Tanvir
AU - Sadeq-ur Rahman, Qazi
AU - Jit, Mark
AU - Newton, Charles R.
AU - Milner, Kate
AU - Gonçalves, Bronner P.
AU - Lawn, Joy E.
AU - Madhi, Shabir A.
AU - Harden, Lois
AU - Ghoor, Azra
AU - Mbatha, Sibongile
AU - Lowick, Sarah
AU - Laughton, Barbara
AU - Jaye, Tamara
AU - Lala, Sanjay G.
AU - Sithole, Pamela
AU - Msayi, Jacqueline
AU - Kumalo, Ntombifuthi
AU - Msibi, Tshepiso Nompumelelo
AU - Arumugam, Asha
AU - Murugesan, Nandhini
AU - Rajendraprasad, Nandhini
AU - Priya, Mohana
AU - Adan, Adam Mabrouk
AU - Katana, Patrick Vidzo
AU - Mwangome, Eva
AU - Mucasse, Humberto
AU - Aerts, Celine
AU - Massora, Sergio
AU - Medina, Valeria
AU - Rojas, Andrea
AU - Amado, Daniel
AU - Llapur, Conrado J.
N1 - Funding Information:
SRP reports additional finding from Bill & Melinda Gates Foundation on Covid-19 related projects. ZD and SL report subawards from the London School of Hygiene & Tropical Medicine (LSHTM) to the Wits Health Consortium. SS and HBJ report subawards from LSHTM to Christian Medical College. QB and AB reports subawards from LSHTM to ISGlobal and Centro de Investigação em Saúde de Manhiça. AA and CN reports subawards from the LSHTM to the University of Oxford. CRN. reports subawards from LSHTM to Kenya Medical Research Institute, Kilifi, Kenya. CSY reports subawards from LSHTM to Fundación INFANT. RL reports subawards from LSHTM to Fundación INFANT. a grant from Program for Appropriate Technology in Health for a respiratory syncytial virus (RSV) costing study, grants to Fernando Polack from the Bill & Melinda Gates Foundation for estimating the RSV burden of disease, consulting fees and participating for serving on Pfizer’s GBS advisory board and Janssen’s RSV advisory board, payment or honoraria for Janssen’s RSV lecture and Merck’s human papillomavirus lecture, and stock or stock options from iTRIALS. FS reports non-financial support from The Federal University of São Paulo for submitted work and employment by the UK NSC hosted by the Department of Health, who developed the maternal GBS screening policy recommendation in the UK. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Funding Information:
This work was supported by a grant (INV-009018) from the Bill & Melinda Gates Foundation to the London School of Hygiene &Tropical Medicine.
Publisher Copyright:
© 2022 The Author(s)
PY - 2022/5
Y1 - 2022/5
N2 - Background: Data are limited regarding long-term consequences of invasive GBS (iGBS) disease in early infancy, especially from low- and middle-income countries (LMIC) where most cases occur. We aimed to estimate risk of neurodevelopmental impairment (NDI) in children with a history of iGBS disease. Methods: A multi-country matched cohort study was undertaken in South Africa, India, Mozambique, Kenya, and Argentina from October 2019 to April 2021. The exposure of interest was defined as a history of iGBS disease (sepsis or meningitis) before 90 days of age, amongst children now aged 1·5–18 years. Age and sex-matched, children without history of GBS were also recruited. Age-appropriate, culturally-adapted assessments were used to define NDI across multiple domains (cognitive, motor, hearing, vision, emotional-behaviour, growth). Pooled NDI risk was meta-analysed across sites. Association of iGBS exposure and NDI outcome was estimated using modified Poisson regression with robust variance estimator. Findings: Amongst 138 iGBS survivors and 390 non-iGBS children, 38·1% (95% confidence interval [CI]: 30·0% – 46·6%) of iGBS children had any NDI, compared to 21·7% (95% CI: 17·7% - 26·0%) of non- iGBS children, with notable between-site heterogeneity. Risk of moderate/severe NDI was 15·0% (95% CI: 3·4% - 30·8%) among GBS-meningitis, 5·6% (95% CI: 1·5% - 13·7%) for GBS-sepsis survivors. The adjusted risk ratio (aRR) for moderate/severe NDI among iGBS survivors was 1.27 (95% CI: 0.65, 2.45), when compared to non-GBS children. Mild impairment was more frequent in iGBS (27.6% (95% CI: 20.3 – 35.5%)) compared to non-GBS children (12.9% (95% CI: 9.7% - 16.4%)). The risk of emotional-behavioural problems was similar irrespective of iGBS exposure (aRR=0.98 (95% CI: 0.55, 1.77)). Interpretation: Our findings suggest that iGBS disease is on average associated with a higher risk of moderate/severe NDI, however substantial variation in risk was observed between sites and data are consistent with a wide range of values. Our study underlines the importance of long-term follow-up for at-risk neonates and more feasible, standardised assessments to facilitate diagnosis in research and clinical practice. Funding: This work was supported by a grant (INV-009018) from the Bill & Melinda Gates Foundation to the London School of Hygiene &Tropical Medicine.
AB - Background: Data are limited regarding long-term consequences of invasive GBS (iGBS) disease in early infancy, especially from low- and middle-income countries (LMIC) where most cases occur. We aimed to estimate risk of neurodevelopmental impairment (NDI) in children with a history of iGBS disease. Methods: A multi-country matched cohort study was undertaken in South Africa, India, Mozambique, Kenya, and Argentina from October 2019 to April 2021. The exposure of interest was defined as a history of iGBS disease (sepsis or meningitis) before 90 days of age, amongst children now aged 1·5–18 years. Age and sex-matched, children without history of GBS were also recruited. Age-appropriate, culturally-adapted assessments were used to define NDI across multiple domains (cognitive, motor, hearing, vision, emotional-behaviour, growth). Pooled NDI risk was meta-analysed across sites. Association of iGBS exposure and NDI outcome was estimated using modified Poisson regression with robust variance estimator. Findings: Amongst 138 iGBS survivors and 390 non-iGBS children, 38·1% (95% confidence interval [CI]: 30·0% – 46·6%) of iGBS children had any NDI, compared to 21·7% (95% CI: 17·7% - 26·0%) of non- iGBS children, with notable between-site heterogeneity. Risk of moderate/severe NDI was 15·0% (95% CI: 3·4% - 30·8%) among GBS-meningitis, 5·6% (95% CI: 1·5% - 13·7%) for GBS-sepsis survivors. The adjusted risk ratio (aRR) for moderate/severe NDI among iGBS survivors was 1.27 (95% CI: 0.65, 2.45), when compared to non-GBS children. Mild impairment was more frequent in iGBS (27.6% (95% CI: 20.3 – 35.5%)) compared to non-GBS children (12.9% (95% CI: 9.7% - 16.4%)). The risk of emotional-behavioural problems was similar irrespective of iGBS exposure (aRR=0.98 (95% CI: 0.55, 1.77)). Interpretation: Our findings suggest that iGBS disease is on average associated with a higher risk of moderate/severe NDI, however substantial variation in risk was observed between sites and data are consistent with a wide range of values. Our study underlines the importance of long-term follow-up for at-risk neonates and more feasible, standardised assessments to facilitate diagnosis in research and clinical practice. Funding: This work was supported by a grant (INV-009018) from the Bill & Melinda Gates Foundation to the London School of Hygiene &Tropical Medicine.
KW - Disability
KW - Group B streptococcus
KW - Impairment
KW - Infants
KW - Meningitis
KW - Neurodevelopment
KW - Sepsis
KW - children
UR - http://www.scopus.com/inward/record.url?scp=85129986643&partnerID=8YFLogxK
U2 - 10.1016/j.eclinm.2022.101358
DO - 10.1016/j.eclinm.2022.101358
M3 - Article
AN - SCOPUS:85129986643
SN - 2589-5370
VL - 47
JO - eClinicalMedicine
JF - eClinicalMedicine
M1 - 101358
ER -